Point Mutations in the Endothelial Protein C Receptor (EPCR) Promoter

Thromb Haemost 2002; 87(06): 1085-1086
DOI: 10.1055/s-0037-1613142

Letters to the Editor

Schattauer GmbH

Eugenia Biguzzi

¹Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, I.R.C.C.S. Maggiore Hospital and University of Milano, Italy

²Oklahoma Medical Research Foundation, Howard Hughes Medical Institute, Oklahoma City, Oklahoma, USA

,

Jian-Ming Gu

²Oklahoma Medical Research Foundation, Howard Hughes Medical Institute, Oklahoma City, Oklahoma, USA

,

Giuliana Merati

¹Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, I.R.C.C.S. Maggiore Hospital and University of Milano, Italy

,

Naomi L. Esmon

²Oklahoma Medical Research Foundation, Howard Hughes Medical Institute, Oklahoma City, Oklahoma, USA

,

Charles T. Esmon

²Oklahoma Medical Research Foundation, Howard Hughes Medical Institute, Oklahoma City, Oklahoma, USA

References
1 Biguzzi E, Merati G, Liaw PCY, Bucciarelli P, Oganesyan N, Qu Dongfeng, Gu Jian-Ming, Fetiveau R, Esmon CT, Mannucci PM, Faioni EM. A 23 bp insertion in the Endothelial Protein C Receptor (EPCR) gene impairs EPCR function. Thromb Haemost 2001; 86: 945-8.
2 Edgell CJ, McDonald CC, Graham JB. Permanent cell line expressing human factor VHI-related antigen established by hybridization. Proc Natl Acad Sci USA 1983; 80 (12) 3734-7.
3 Dignam JD, Lebovitz RM, Roeder R. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11: 1475-89.